Research Analysts Set Expectations for STOK Q1 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Stoke Therapeutics in a research note issued on Tuesday, March 18th. Leerink Partnrs analyst M. Goodman expects that the company will post earnings per share of ($0.49) for the quarter. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics' Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.79) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at $0.55 EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million.

STOK has been the subject of several other research reports. Chardan Capital restated a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. HC Wainwright restated a "buy" rating and set a $47.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of "Buy" and an average price target of $23.00.

Remove Ads

Stoke Therapeutics Trading Down 6.6 %

Shares of STOK traded down $0.55 on Friday, reaching $7.74. 1,074,611 shares of the company's stock traded hands, compared to its average volume of 839,762. The stock's 50 day simple moving average is $9.46 and its two-hundred day simple moving average is $11.35. The stock has a market cap of $418.56 million, a PE ratio of -3.69 and a beta of 0.99. Stoke Therapeutics has a 52-week low of $6.29 and a 52-week high of $17.58.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC boosted its position in shares of Stoke Therapeutics by 145.3% during the third quarter. Barclays PLC now owns 79,740 shares of the company's stock valued at $980,000 after purchasing an additional 47,239 shares in the last quarter. Geode Capital Management LLC lifted its position in Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company's stock valued at $10,705,000 after buying an additional 76,661 shares during the period. State Street Corp boosted its holdings in shares of Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company's stock valued at $21,248,000 after buying an additional 137,145 shares in the last quarter. RTW Investments LP grew its position in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after buying an additional 427,447 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock valued at $936,000 after acquiring an additional 71,647 shares during the period.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,532 shares of company stock valued at $143,332. Insiders own 11.30% of the company's stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.